Market Overview

Why BioMarin Pharmaceutical Is Surging


BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) jumped over 14 percent on Friday, as a buyout rumor surfaced just ahead of an apparently routine conference call with analysts concerning its developmental drug programs.

Separately, Deutsche Bank's Robyn Karnauskas published a note on Friday raising her target 55 percent to $140.

BioMarin changed hands recently at $129.51, up $13.96. The stock is up 45 percent year to date.

Ben Harrington, a former business editor at the Daily Telegraph who now writes for the blog Betaville, cited unnamed sources on Thursday claiming that Ireland-based Shire PLC (ADR) (NASDAQ: SHPG) was "weighing a $65 billion merger with BioMarin."

Related Link: What Evercore Is Watching At BioMarin Pharmaceutical

The Novato, California-based BioMarin has a market capitalization of about $20.9 billion versus Shire's $40 billion cap.

Karnauskas' note focused on BioMarin's drug development, and didn't comment on Harrington's report. But she put the company's potential take-out value at $170 a share.

Data on several development programs will act as catalysts on the stock in the upcoming year, during which Karnauskas expects the shares will be volatile.

"Not everything in the pipeline needs to work for the stock to work, or to command and M&A premium," said Karnauskas, who reiterated a Buy rating.

A BioMarin conference call with analysts was slated to start at 10 a.m. Friday.

Latest Ratings for BMRN

Sep 2020Truist SecuritiesMaintainsBuy
Aug 2020Morgan StanleyMaintainsEqual-Weight
Aug 2020Canaccord GenuityMaintainsBuy

View More Analyst Ratings for BMRN
View the Latest Analyst Ratings


Related Articles (BMRN + SHPG)

View Comments and Join the Discussion!

Posted-In: biomarinAnalyst Color News Rumors Price Target Reiteration Analyst Ratings Movers

Latest Ratings

JBLRBC CapitalMaintains38.0
COSTRBC CapitalMaintains412.0
COSTMKM PartnersMaintains325.0
MTNTruist SecuritiesMaintains243.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at